Glaukos has claimed a series of regulatory clearances in Europe for its micro-scale surgical implants to treat patients with ...

The iStent infinite Trabecular Micro-Bypass System Model iS3 is for minimising IOP in those with primary open-angle glaucoma.

The glaucoma treatment market is expected to witness steady growth between 2025 and 2035, driven by the increasing prevalence of glaucoma, advancements in treatment options, and rising awareness about ...

Glaukos (NYSE:GKOS) announced that it received EU MDR certification for its iStent Infinite, along with several other ...

Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

Glaukos Q1 results beat expectations, and the company is delivering on a robust pipeline as it continues to build an ...

Foreword The only time is now. Every “now” is unique. Responsible persons ask themselves, “How can I act well now?” The answers will differ for every person, because just as every situation is unique, ...

He highlights that glaucoma is often more manageable with medical therapy in dogs than in cats, depending on the cause. Bergstrom also discusses the limited utility of latanoprost—a key medication in ...

The company’s lead program, QLS-111, is designed to address a significant unmet need in glaucoma treatment by targeting EVP. For more information, please visit www.qlaris.bio . Contacts ...

The most recent iStent product, Infinite, allows multiple stents to be used to treat glaucoma as a standalone procedure. iDose is a tiny implant that allows for the continuous delivery of drugs to ...

Aim: To estimate the number of people with open angle (OAG) and angle closure glaucoma (ACG) in 2010 and 2020. Methods: A review of published data with use of prevalence models. Data from population ...